Published • loading... • Updated
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics said its lead programs continued to advance as it reported quarterly results and outlined cash runway and development plans.
Summary by MarketBeat
4 Articles
4 Articles
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear
·Sioux Falls, United States
Read Full Article
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from ...
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenueSelected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move…
Coverage Details
Total News Sources4
Leaning Left2Leaning Right1Center1Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 25%
R 25%
Factuality
To view factuality data please Upgrade to Premium
